Form 4: Acrivon Therapeutics Director Santhosh Palani Reports Stock Option Grant

Director Santhosh Palani of Acrivon Therapeutics reports the acquisition of stock options.

Summary

• On March 4, 2024, Santhosh Palani, a director of Acrivon Therapeutics, Inc., was granted stock options to purchase 32,500 shares of common stock.
• The exercise price of the options is $5.05 per share.
• The options vest in 36 equal monthly installments starting March 4, 2024, and will be fully vested on the third anniversary, subject to continuous service.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting a positive alignment of interests between management and shareholders. It's a routine event, hence a moderately positive sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

The vesting schedule suggests a long-term commitment from the director to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 36 months is typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation strategy.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the director to work towards increasing the company's value.

Key Dates